Navigation Links
Arthrex, Depuy Mitek, and Smith & Nephew Lead the $1.5 Billion U.S. Orthopedic Soft Tissue Market, Reports iData Research
Date:6/24/2013

Vancouver, BC (PRWEB) June 24, 2013

According to statistics released by the American Academy of Orthopaedic Surgeons along with the American Orthopaedic Society for Sports Medicine, there are approximately 150,000 ACL (anterior cruciate ligament) injuries each year in the United States. One of the main causes of ACL injury is direct impact to the knee, which often happens in high-contact sports such as football or basketball. However, most ACL tears happen when there is no contact between the knee and another object, and are instead a result of hyperextension or rapid change in direction, which happens often in agility sports. Since stitching the ligament together hardly ever proves to be successful, several techniques have been developed which involve reconstructing the ACL by building a ligament out of a graft substitute such as allografts, autografts, or xenografts. The high procedural costs of these surgeries account for a yearly healthcare expenditure of half a billion dollars.

According to the latest intelligence from iData Research, the leading authority in global market research, the market for orthopedic soft tissue repair is valued at over $1.5 billion, with the ACL/PCL reconstruction and fixation markets contributing to a significant portion of the total market. The two different types of reconstructions that can be done use either bone-patellar bone tendon-bone (BTB) grafts or soft tissue graft methods. “While BTB grafts are considered the gold standard in reconstruction procedures, soft tissue grafts produce less anterior knee pain, but are more prone to becoming stretched over time,” explains Dr. Kamran Zamanian, CEO of iData Research. For procedures using BTB grafts, only interference screws are used for anchoring the tendon or ligament of the graft to the bone. In contrast, for procedures that use soft tissue grafts, a variety of other devices are available to fixate the graft to the femoral and tibial tunnels.

The Muscoskeletal Transplant Foundation (MTF) led the ACL/PCL reconstruction market share in 2012. MTF is the largest tissue bank organization in the U.S. and is a non-profit service organization. RTI Biologics followed close behind, with a healthy level of growth that can be in part attributed to their release of 18 new implants and implant enhancements in 2012. In the fixation segment, Arthrex was the market leader, based on their high market share in nearly all material segments, particularly in the lucrative biocomposite segment. Depuy Mitek came in close second, with their Bio-INTRAFIX™ being considered as the gold standard fixation product for soft tissue tibial fixation. Moreover, Smith & Nephew was a major player, mostly due to their strength in the cortical fixation segment which they pioneered with the ENDOBUTTON® cortical fixation device. Other notable competitors in the reconstruction and fixation markets were AlloSource, LifeNet Health, ConMed Linvatec, Stryker, Biomet, Cayenne Medical, and ArthroCare.

A synopsis for each market intelligence publication in the global series on the Markets for Orthopedic Soft Tissue covering the U.S., China, India, Japan, Brazil, as well as 15 European countries is available here. The full series provides a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success strategies in each market and segment. The reports also cover markets for: cartilage repair, meniscal repair, rotator cuff repair, shoulder labrum repair, rotator cuff graft reinforcement devices, hip arthroscopy, and biceps tenodesis.

About iData Research

iData Research is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: arthroscopy, orthopedic biomaterials, orthopedic trauma, soft tissue repair, spinal implants and MIS, and orthopedic large and small joints.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10865382.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
2. US Drug Watchdog Now Offers To Get A Free Legal Review For All DePuy ASR Recipients Who Received A Letter From Broadspire About Their Recalled DePuy Hip Implant
3. US Drug Watchdog Now Offers To Help All Recipients Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Get To The Best Attorneys Regardless If Their Device Has Failed
4. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Know The Symptoms Of A Failure And Offers To Name The Best Lawyers & Law Firms For Failure Victims
5. US Drug Watchdog Now Offers To Help Every Recipient Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Who Had To Go Through Revision Surgery Get To The Best Lawyers
6. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
7. US Drug Watchdog Now Offers To Help All Recalled DePuy ASR Hip Implant Recipients Get To The Best Attorneys Out Of Fear These Recipients Won't Be Compensated
8. The US Drug Watchdog Now Offers To Help All Recipients Of Recalled DePuy ASR Hip Implant Get To The Best Attorneys Because Time Could Run Out To Get Them Identified
9. US Drug Watchdog Says Its Critical All DePuy Pinnacle Hip Implant Recipients Know The Symptoms Of A Failure And They Offer The Names Of The Best Attorneys For Victims
10. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Get A Blood Test For Elevated Levels Of Cobalt Or Chromium and to Call Them If The Levels Are high
11. US Drug Watchdog Now Urges All DePuy Pinnacle And DePuy Hip Implant Recipients To Call Them For The Names Of The Best Law Firms Before Time Runs Out To Get Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: